CASI Pharmaceuticals Announces Changes in Board Governance

Core Viewpoint - CASI Pharmaceuticals has appointed James Huang as Non-Executive Chairman of the Board, effective November 17, 2025, marking a significant leadership transition within the company [1] Group 1: Leadership Changes - James Huang, previously an independent board member, has been unanimously voted in as Non-Executive Chairman of CASI Pharmaceuticals [1] - Dr. Wei-Wu He will step down from his role as Executive Chairman but will continue to serve as a member of the Board of Directors [1]